Skip to content

US · PDSB · BIOTECHNOLOGY

PDS Biotechnology Corporation (PDSB) intrinsic value and stock valuation

$0.78as of 2026-11-21 · Mkt cap 40.64M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PDS Biotechnology Corporation DCF and intrinsic value

InvestorsCraft values PDSB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PDSB’s statements →

PDS Biotechnology Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Princeton, NJ 08540 pdsbiotech.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-34.5M
20122025
Free cash flow
-$-27.75B
20122025
Total equity
$9.25M-19.4% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-31.54M-$-36.32M-$-43.05M-$-41.67M-$-21.44M
Net income-$-34.5M-$-37.61M-$-42.94M-$-40.85M-$-16.92M
EPSd-$-743.86K-$-1.03M-$-1.39M-$-1.43M-$-660.94K
Operating cash flow-$-27.75B-$-35.03M-$-33.64M-$-25.71M-$-12.49M
Capital expenditure$0.00-$-30K$0.00$0.00$0.00
Free cash flow-$-27.75B-$-35.06M-$-33.64M-$-25.71M-$-12.49M
Total assets$30.5M$45.4M$59.4M$77M$67.2M
Total debt$16.9M$21.8M$23.9M$23.5M$490K
Net debt-$-9.79M-$-19.86M-$-32.71M-$-50.35M-$-64.75M
Total equity$9.25M$19M$26.1M$44M$63.2M
Cash and short-term investments$26.7M$41.7M$56.6M$73.8M$65.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$60K$60K$0.00$0.00
Gross profit$0.00-$-60K-$-60K$0.00$0.00
Research and development expenses$19M$22.6M$27.8M$29.4M$11.3M
Selling, general and administrative expenses$12.5M$13.7M$15.3M$12.2M$10.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$31.5M$36.3M$43.1M$41.7M$21.4M
Cost and expenses$31.5M$36.3M$43.1M$41.7M$21.4M
Interest income$1.22M$2.52M$2.9M$940K$0.00
Interest expense$5.34M$4.67M$4.21M$1.32M$0.00
Depreciation and amortization$20K$60K$60K$0.00$10K
Ebitda-$-30.3M-$-33.75M-$-40.09M-$-40.74M-$-21.43M
Operating income-$-31.54M-$-36.32M-$-43.05M-$-41.67M-$-21.44M
Total other income/expenses, net-$-4.12M-$-2.16M-$-1.3M-$-380K$0.00
Income before tax-$-35.67M-$-38.48M-$-44.35M-$-42.05M-$-21.43M
Income tax expense-$-1.17M-$-870K-$-1.41M-$-1.2M-$-4.52M
Net income-$-34.5M-$-37.61M-$-42.94M-$-40.85M-$-16.92M
Weighted average shares outstanding$46.4M$36.5M$31M$28.6M$25.6M
Weighted average diluted shares outstanding$46.4M$36.5M$31M$28.6M$25.6M
Balance sheet
20252024202320222021
Cash and short-term investments$26.7M$41.7M$56.6M$73.8M$65.2M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$28.3M$45.1M$59.1M$76.5M$66.8M
Property, plant and equipment, net$240K$300K$340K$530K$360K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.24M$300K$340K$530K$360K
Total assets$30.5M$45.4M$59.4M$77M$67.2M
Accounts payable$3.57M$1.68M$6.98M$1.22M$1.31M
Short-term debt$5.17M$12.6M$4.22M$290K$260K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.48M$17.1M$13.6M$9.82M$3.76M
Long-term debt$11.8M$9.27M$19.6M$23.2M$230K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$11.8M$9.27M$19.6M$23.2M$230K
Capital lease obligations$60K$120K$180K$450K$490K
Total liabilities$21.2M$26.4M$33.3M$33M$3.99M
Common stock$20K$10K$10K$10K$10K
Retained earnings-$-216.61M-$-182.11M-$-144.5M-$-101.56M-$-60.7M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$9.25M$19M$26.1M$44M$63.2M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$16.9M$21.8M$23.9M$23.5M$490K
Net debt-$-9.79M-$-19.86M-$-32.71M-$-50.35M-$-64.75M
Cash flow statement
20252024202320222021
Net income-$-34.5B-$-37.61M-$-42.94M-$-40.85M-$-16.92M
Depreciation and amortization$1.55B$20K$20K$0.00$10K
Stock-based compensation$4.11B$6.85M$7.61M$5.2M$4.11M
Change in working capital-$-380K-$-5.75M-$-200K$4.47M$80K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.89M-$-5.3M$5.76M-$-90K-$-110K
Net cash provided by operating activities-$-27.75B-$-35.03M-$-33.64M-$-25.71M-$-12.49M
Investments in property, plant and equipment$0.00-$-30K$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-30K$0.00$0.00$0.00
Common stock issued$20.3M$22.6M$16.1M$9.86M$48.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.8B$20.2M$16.4M$34.3M$48.9M
Net change in cash-$-14.98B-$-14.87M-$-17.26M$8.58M$36.4M
Cash at end of period$26.7B$41.7M$56.6M$73.8M$65.2M
Operating cash flow-$-27.75B-$-35.03M-$-33.64M-$-25.71M-$-12.49M
Capital expenditure$0.00-$-30K$0.00$0.00$0.00
Free cash flow-$-27.75B-$-35.06M-$-33.64M-$-25.71M-$-12.49M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PDS Biotechnology Corporation

        PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.

        CEO
        Frank K. Bedu-Addo
        Employees
        21
        Beta
        1.58

        Explore

        Frequently asked questions

        What is the intrinsic value of PDS Biotechnology Corporation (PDSB)?

        InvestorsCraft does not currently publish an intrinsic value for PDSB. How the IC value is calculated.

        Is PDSB undervalued?

        InvestorsCraft does not publish an undervaluation signal for PDSB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.